New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTirzepatide vs Pinealon

Tirzepatide vs Pinealon

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Tirzepatide
Cognitive EnhancementAnti-Aging & Longevity
Pinealon
Summary
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation, designed to penetrate the blood-brain barrier and exert neuroprotective, neurogenic, and anti-aging effects by regulating pineal gland and brain cell function.
Half-Life
~5 days
Short (peptides rapidly degraded), but epigenetic/gene regulatory effects persist
Admin Route
SubQ
SubQ, Oral, Intranasal
Research
Typical Dose
2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
5–10 mg (oral) or 50–100 mcg (SC)
Frequency
Once weekly, subcutaneous
Once daily for 10 days
Key Benefits
  • Average 21% body weight reduction at highest dose (SURMOUNT-1)
  • Superior to semaglutide in head-to-head SURPASS trials
  • Dual GIP/GLP-1 mechanism for enhanced metabolic control
  • Significant reduction in HbA1c for type 2 diabetes
  • Improved cardiovascular risk markers
  • Reduces visceral fat preferentially
  • FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
  • Weekly dosing
  • Neuroprotection against oxidative stress and hypoxia
  • Promotes neuronal regeneration and repair
  • Improves memory and cognitive function
  • Enhances sleep quality via melatonin regulation
  • Anti-aging effects on brain cells
  • May slow cognitive decline in neurodegeneration
  • Improves cerebrovascular circulation
  • Reduces neuroinflammation
Side Effects
  • Nausea (most common during titration)
  • Vomiting
  • Diarrhea or constipation
  • Abdominal pain
  • +3 more
  • Excellent safety profile in clinical use
  • Rare: mild drowsiness
  • Transient mild headache at initiation
  • Injection site reaction (SC)
Stacks With